AG
CYTO

Advisor Group’s Altamira Therapeutics Ltd CYTO Stock Holding History

Advisor Group’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$277K – 4650
2016
Q2 		$277K Buy
+1
New +$299K 0.01% 1234

Other funds holding CYTO

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Advisor Group's CYTO Position: Q3 2016 in Review

Advisor Group sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2016, closing a stake of 1 share — an estimated $277K sold.

Advisor Group first reported a position in CYTO in Q2 2016 and held it in 1 quarter. The position peaked at $277K in Q2 2016. 3 funds tracked by Wall St. Rank hold CYTO as of Q3 2016.

  • Advisor Group reported no remaining Altamira Therapeutics Ltd position as of Q3 2016 after selling out during the quarter.
  • Advisor Group sold 1 Altamira Therapeutics Ltd share in Q3 2016, an estimated $277K.
  • Advisor Group first reported a position in Altamira Therapeutics Ltd in Q2 2016 and held it in 1 quarter.
  • Advisor Group's Altamira Therapeutics Ltd position peaked at $277K in Q2 2016.
  • 3 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2016.

Based on Advisor Group's 13F filing for Q3 2016, filed 9 Nov 2016.